Arrow Mark Colorado Holdings LLC Metacrine, Inc. Transaction History

Arrow Mark Colorado Holdings LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.61 - $3.84 $2 Million - $2.94 Million	-764,674 Reduced 73.09%	281,467 $965,000
Q2 2021 Aug 16, 2021	SELL	$3.37 - $5.73 $46,172 - $78,506	-13,701 Reduced 1.29%	1,046,141 $3.98 Million
Q1 2021 May 17, 2021	BUY	$6.2 - $11.0 $195,591 - $347,017	31,547 Added 3.07%	1,059,842 $6.57 Million
Q4 2020 Feb 16, 2021	SELL	$7.75 - $11.42 $70,943 - $104,538	-9,154 Reduced 0.88%	1,028,295 $8.08 Million
Q3 2020 Nov 16, 2020	BUY	$9.38 - $11.76 $9.73 Million - $12.2 Million	1,037,449 New	1,037,449 $10.6 Million

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.